Biogen: FDA grants fast track status to Biogen's BIIB080 for Alzheimer's

This status is aimed at facilitating the development and speeding up the review process for drugs that address serious conditions and fill unmet medical needs. Biogen development head The post FDA grants fast track status to Biogen's BIIB080 for Alzheimer's appeared first on Pharmaceutical Business review.